@entity9229 ( @entity14137 ) is a long-acting @entity935 agonist. In the first national study with @entity14137 --as part of an international multicentric study--39 adult and adolescent females (16 to 44 years old) with hyperprolactinemic @entity2588 (18 microadenomas and 21 idiopathic @entity4089 ) were evaluated. @entity14137 or @entity2847 ( @entity32896 ) was administered for 24 weeks: over 8 weeks, treatment was given under double-blind conditions, and over the remaining 16 weeks (open period) 18 @entity1 received @entity14137 and 21 received @entity32896 as a result of a random distribution. Maximum dosage: @entity14137 = 1.5 mg in 2 or 3 weekly doses; @entity32896 = up to 10 mg in 2 daily doses. Prolactin was measured at base line and 2, 4, 6, 8, 12, 14, 16, 20 and 24 weeks after the initiation of treatment. When @entity3556 was restored, @entity1420 was measured as an ovulation sign. The 4 adolescents continued with @entity14137 treatment for 1 more year. Prolactin was statistically evaluated according to @entity1 Whitney Test (general population) or Wilcoxon Test (adolescents). There were no significant differences between basal levels of prolactin (ng/ml) in @entity1 treated with @entity32896 or @entity14137 : (173.86 +/- 28.23 and 152.11 +/- 14.06 respectively); at the fourth week of treatment the decrease was smaller (p = 0.005) in @entity1 treated with @entity32896 (36.36 +/- 5.71) than in those treated with @entity14137 (14.06 +/- 3.60) and at 24 weeks differences disappeared: @entity32896 = 19.88 +/- 4.48 and @entity14137 = 9.63 +/- 2.62 (p = NS). The adolescents showed a marked decrease in prolactin with no significant differences between @entity32896 and @entity14137 : basal levels = 168.17 +/- 75.47 and 213 +/- 96.99 (p = NS); 4 weeks = 48.00 +/- 8.72 and 35.00 +/- 12.58 (p = NS); 24 weeks = 34.33 +/- 10.17 and 21.75 +/- 7.23 respectively. At 48 weeks (23.25 +/- 11.23) levels remained the same as those of week 24 (p = NS). Some @entity1 treated with @entity32896 had @entity390 , @entity391 and epigastralgia; these symptoms were not observed with @entity14137 . All @entity1 resumed menstrual cycles, except one treated with @entity32896 ; 6 @entity1 treated with @entity14137 became pregnant, and the 5 @entity1 who continued under our control gave birth to healthy @entity1 . It is concluded that @entity14137 is a useful therapy. This is specially true for adolescents (an age group difficult to manage) because of its easy administration and the almost complete absence of side effects.

[Treatment of hyperprolactinemic XXXX with @entity9229 ].

@entity1 :: ('9606', 'Species') :: ['patients', 'infants', 'Man'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinemias'] @entity14137 :: ('MESH:C014396', 'Chemical') :: ['CAB'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine'] @entity32896 :: ('CHEBI:59346', 'Chemical') :: ['BEC'] @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['Cabergoline'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomits'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']
@entity2588 :: (MESH:D000568,Disease) :: ['amenorrhea']
